Paediatric Section, Department of Life and Reproduction Sciences, University of Verona, Verona, Italy.
Int J Immunopathol Pharmacol. 2013 Oct-Dec;26(4):883-7. doi: 10.1177/039463201302600406.
The purpose of the present study was to investigate the possible anti-oxidant effect(s) of Ambroxol on neutrophils activated by ligand-binding of the drug with membrane-associated adhesion integrin CD11a and to estimate dose-response changes in oxygen free radical production. The amount of free radical production by anti-CD11a- and anti-CD4-coated neutrophils stimulated with N-formyl-methionyl-leucyl-phenylalanine (FMLP) and challenged with increasing concentration of Ambroxol, was evaluated within a time frame of 90 minutes. A significant dose-dependent effect response of Ambroxol on O2‾ production by cells coated with anti-CD11a antibody was observed. This preliminary study opens a new perspective on the therapeutic role of Ambroxol as an antioxidant drug and for its potential use in controlling oxidative stress, particularly in leukocyte-dependent inflammation.
本研究旨在探讨安布索醇（Ambroxol）与膜结合黏附整合素 CD11a 配体结合后激活的中性粒细胞的可能抗氧化作用，并评估其在氧自由基产生方面的剂量反应变化。在 90 分钟的时间框架内，评估了用抗 CD11a 和抗 CD4 包被的中性粒细胞刺激物（N-甲酰基-甲硫氨酸-亮氨酸-苯丙氨酸（FMLP））和用不同浓度的安布索醇挑战后，自由基的产生量。观察到安布索醇对用抗 CD11a 抗体包被的细胞中 O2‾产生的显著剂量依赖性效应反应。这项初步研究为安布索醇作为抗氧化药物的治疗作用及其在控制氧化应激方面的潜在用途开辟了新的视角，特别是在白细胞依赖性炎症中。
